Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cardinale

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
ESC Heart Failure|May 3, 2020
Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trialJennifer M T A Meessen, Daniela Cardinale, Fabio Ciceri, et al.
European Heart Journal|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Heart Journal. Cardiovascular Imaging|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
Elife|December 7, 2022
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growthLuca Costantino, Stefania Ferrari, Matteo Santucci, et al.
European Journal of Heart Failure|October 2, 2020
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Christian Mueller, Jelena Čelutkienė, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure|May 29, 2020
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology SocietyAlexander R Lyon, Susan Dent, Susannah Stanway, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
ESC Heart Failure|May 3, 2020
Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trialJennifer M T A Meessen, Daniela Cardinale, Fabio Ciceri, et al.
European Heart Journal|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
European Heart Journal. Cardiovascular Imaging|August 26, 2022
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R Lyon, Teresa López-Fernández, Liam S Couch, et al.
Elife|December 7, 2022
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growthLuca Costantino, Stefania Ferrari, Matteo Santucci, et al.
European Journal of Heart Failure|October 2, 2020
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Christian Mueller, Jelena Čelutkienė, et al.
European Journal of Heart Failure|August 1, 2024
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo Gabriele Tocchetti, Dimitrios Farmakis, Yvonne Koop, et al.
European Journal of Heart Failure|May 29, 2020
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology SocietyAlexander R Lyon, Susan Dent, Susannah Stanway, et al.
Pageof 11